Dupixent – which is due for a verdict from the FDA as a COPD therapy later this month – was cleared for adults with uncontrolled COPD with raised blood eosinophils, while Ohtuvayre can be used ...

shortly after Verona Pharma got the go-ahead from the US FDA for its PDE 3/4 inhibitor Ohtuvayre (ensifentrine). Dupixent becomes the first-ever targeted therapy for patients with COPD ...